Scienture Holdings, Inc. (SCNX) · Oct 19, 2026 · Earnings

Scienture earnings miss, but Nasdaq listing compliance restored

Miss — Preliminary revenue $1.22M vs ~$1.58M consensus

Scienture’s preliminary Q3 earnings show sharp revenue growth but miss consensus, while the company separately regains Nasdaq’s $1 bid-price compliance.

Scienture is moving from launching its first specialty products to scaling a two-product commercial pharmaceutical business built around Arbli and the newly launched REZENOPY; Q2 revenue was already accelerating, and the company’s next test is whether that launch momentum becomes repeatable sales.

Revenue growth is real, but the preliminary quarter missed the published bar. Q3 revenue rose sharply from Q2 as REZENOPY began wholesale shipments and Arbli sales continued, but the approximately $1.22 million result was below the roughly $1.58 million consensus estimate. That makes this a growth-positive but earnings-negative update versus expectations.

MetricQ3 2026Comparison / expectation
Preliminary revenue$1.22M~$1.58M consensus
Q2 2026 revenue$344,000Q3 up 256% sequentially
Sequential revenue growth256%Driven by REZENOPY launch and Arbli growth

The commercial story advanced, but the quality of the quarter remains unproven. REZENOPY contributed initial wholesale shipments after its August 2026 launch, giving Scienture a second FDA-approved commercial product and a broader revenue base. But the filing reports only preliminary, unaudited revenue and provides no gross profit, cash-flow, expense, or product-level sales detail, so it does not yet prove that the revenue ramp is translating into improving economics. 〔0〕

Nasdaq compliance removes an immediate listing overhang, but it is confirmation rather than a business catalyst. The company regained the $1 minimum bid-price requirement after ten consecutive trading days above the threshold from October 5 through October 16, closing the matter and keeping its securities listed. 〔1〕 This is helpful for operating continuity and financing flexibility, but it does not change product demand, profitability, or the need to execute commercially.

Bottom line: Scienture’s product launch is producing a meaningful revenue ramp, but Q3 came in below consensus and still lacks the financial detail needed to validate the economics. Nasdaq compliance is resolved, making the overall filing mixed rather than a clean earnings win.

What to watch next

Q3 10-Q, expected November 11, 2026

Original filing on SEC EDGAR

More Scienture Holdings, Inc. news

Scienture earnings miss, but Nasdaq listing compliance restored | SCNX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.